Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of SMP-986 for overactive bladder syndrome
2006-003730-15Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Afacifenacin in overactive bladder (OAB) (5 arms), sponsored by Sumitomo Pharma. Primary endpoint: Change from baseline to week 8 in mean number of voids per 24 hours. Started Sep 2006; status: completed.
02
Drugs
Afacifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2006-003730-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003730-15.